Carlos Slim Foundation announces an agreement with AstraZeneca to support the production of the COVID-19 vaccine in Argentina, Mexico and distribution, without economic benefit, in Latin America
The agreement will provide $ 150 million of doses and shipments are expected to begin in the first half of 2021.
AstraZeneca will work in partnership with partners to supply the vaccine so that it is equitably available.
This initiative represents an important milestone in the response to the COVID-19 pandemic to support broad access to the vaccine.
The Carlos Slim Foundation stated: “Based on the research of the University of Oxford and AstraZeneca, a potential vaccine is in development that is in phase 3 with encouraging expectations, consequently we join the effort for its production in Mexico and Argentina with the end for the supply to Latin America to begin. If its efficacy and safety are proven and approved by the health authorities, it would contribute decisively to prevent further loss of life, and would allow a return to normality ”.
